Estradiol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Estradiol
- Estradiol: From Primary Ovarian Failure and Menopausal Conditions to Symptomatic Fragile X Syndrome in Female Carriers
Estradiol: From Primary Ovarian Failure and Menopausal Conditions to Symptomatic Fragile X Syndrome in Female Carriers
One-Sentence Summary
Estradiol is an estrogen hormone originally used for primary ovarian failure, postmenopausal osteoporosis and postmenopausal atrophic vaginitis. The TxGNN model predicts it may be effective for the symptomatic form of fragile X syndrome in female carriers, which most likely means fragile X-associated primary ovarian insufficiency. This prediction currently rests on model output alone: 0 clinical trials and 0 publications were found.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Primary ovarian failure, postmenopausal osteoporosis, postmenopausal atrophic vaginitis, acne (from the knowledge graph; the Singapore licences list no indication text) |
| Predicted New Indication | Symptomatic form of fragile X syndrome in female carrier |
| TxGNN Prediction Score | 98.76% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 10 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, estradiol is the main natural estrogen. It replaces the hormone when the ovaries no longer produce enough of it, and its efficacy in primary ovarian failure is established.
Female carriers of an FMR1 premutation can develop fragile X-associated primary ovarian insufficiency (FXPOI). This condition overlaps with estradiol's established use in primary ovarian failure, so hormone replacement is a plausible way to manage the ovarian component, such as estrogen deficiency symptoms and bone health.
This is a reasoned hypothesis, not a demonstrated result. The link comes only from the TxGNN prediction. Estradiol would not treat the underlying genetic condition or its non-ovarian features, such as neurological or cognitive symptoms.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Ten single-ingredient estradiol-containing products hold valid registrations in Singapore. No approved indication text is recorded for any of them. The five main ones are:
| Authorization Number | Product Name | Dosage Form |
|---|---|---|
| SIN11642P | DIVIGEL GEL 1mg/dose | Gel |
| SIN14877P | VAGIFEM® VAGINAL TABLET 10MCG | Film-coated tablet |
| SIN06009P | ESTROFEM TABLET 2 mg | Film-coated tablet |
| SIN06503P | OESTROGEL 0.06% | Gel |
| SIN11644P | DIVIGEL GEL 0.5mg/dose | Gel |
Available forms include topical gels and oral film-coated tablets.
Safety Considerations
- Contraindications flagged in the knowledge graph (not taken from the package insert): hypertension, liver failure and liver disease, kidney disease, gallbladder disease, epilepsy, porphyria, diabetes mellitus and hyperglycaemia, congestive heart failure, hypothyroidism, adrenocortical insufficiency (Addison disease), systemic lupus erythematosus, asthma, anxiety and related disorders, and humoral hypercalcaemia of malignancy. Osteoporosis and postmenopausal osteoporosis also appear in this list even though they are an original indication, so these links should be checked against the label.
- Drug interactions: 100 interactions were recorded, mostly of moderate severity. Examples include:
- Antidiabetic agents: metformin, pioglitazone, acarbose, alogliptin, canagliflozin and dapagliflozin.
- Corticosteroids: hydrocortisone, dexamethasone, betamethasone and budesonide.
- Macrolide and other anti-infective agents: clarithromycin and clotrimazole.
- Other: aprepitant. Cimetidine was classed as a minor interaction.
Please also refer to the package insert for full safety information, as no label warnings or contraindications were available.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high (98.76%), but there are no clinical trials or publications behind it, so the evidence level is L5. The biological idea of hormone replacement for FXPOI is reasonable, yet it is untested here and would address only the ovarian component of the condition.
To proceed, the following is needed:
- A literature and trial search specific to FXPOI or FMR1 premutation carriers and hormone replacement therapy
- Mechanism of action data
- Package insert warnings and contraindications from the Singapore regulator (HSA)
- Assessment of the long-term safety of estrogen in this population, including the KG-flagged contraindications
- Route and formulation selection (oral versus transdermal) for the target population
Of the other indications predicted for estradiol, anovulation is the only one with registered trials. It has a Phase 4 trial of clomiphene plus estradiol (NCT02186782, n=600, status unknown) and reaches evidence level L2. It may be a better candidate for further evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.